SS
ELVN icon

SBI Securities’s Enliven Therapeutics ELVN Stock Holding History

SBI Securities’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.62K Buy
32
+7
+28% +$297 ﹤0.01% 2631
2026
Q1 		$980 Sell
25
-12
-32% -$332 ﹤0.01% 2661
2025
Q4 		$570 Sell
37
-1
-3% -$20 ﹤0.01% 2822
2025
Q3 		$778 Buy
38
+1
+3% +$20 ﹤0.01% 2797
2025
Q2 		$742 Hold
37
– – ﹤0.01% 2805
2025
Q1 		$728 Hold
37
– – ﹤0.01% 2723
2024
Q4 		$833 Buy
+37
New +$959 ﹤0.01% 2690

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

SBI Securities's ELVN Position: Q2 2026 in Review

SBI Securities increased its Enliven Therapeutics (ELVN) stake by 28% in Q2 2026, buying an estimated $297 and bringing the position to 32 shares worth $1.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2631.

SBI Securities first reported a position in ELVN in Q4 2024 and has held it in 7 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • SBI Securities held 32 shares of Enliven Therapeutics worth $1.62K as of Q2 2026.
  • SBI Securities bought 7 Enliven Therapeutics shares in Q2 2026, an estimated $297.
  • Enliven Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2631 holding.
  • SBI Securities first reported a position in Enliven Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.